| P50 | author | William G Wierda | Q64026278 |
| | Michael J. Keating | Q66429598 |
| | Kumudha Balakrishnan | Q114427990 |
| | Viralkumar Patel | Q117256515 |
| P2093 | author name string | Varsha Gandhi | |
| | Mary Ayres | |
| | Elena Bibikova | |
| P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 |
| | Agammaglobulinemia | Q28244575 |
| | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 |
| | Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 |
| | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 |
| | FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia | Q33425207 |
| | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 |
| | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 |
| | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 |
| | Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 |
| | Primary immunodeficiency diseases due to defects in lymphocytes | Q34073630 |
| | The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 |
| | Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells | Q34354339 |
| | The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases | Q34355151 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia | Q35022490 |
| | Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells | Q35080394 |
| | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 |
| | Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets | Q35561060 |
| | Chronic lymphocytic leukemia: revelations from the B-cell receptor. | Q35667038 |
| | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. | Q36021849 |
| | Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets | Q36401453 |
| | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 |
| | BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia | Q36799197 |
| | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 |
| | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 |
| | Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing | Q37635605 |
| | Targeting Bruton's tyrosine kinase in B cell malignancies | Q38198490 |
| | Src family kinases: at the forefront of platelet activation | Q38239258 |
| | Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study | Q38956893 |
| | Imaging of thrombosis and microcirculation in mouse lungs of initial melanoma metastasis with in vivo cryotechnique | Q39046092 |
| | Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. | Q40916348 |
| | Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families | Q41439621 |
| | Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice | Q41541610 |
| | High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 |
| | Intracellular Phospho-Flow cytometry reveals novel insights into TCR proximal signaling events. A comparison with Western blot | Q44540296 |
| | Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. | Q53611739 |
| | Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 |
| | Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 |
| | TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues. | Q54506056 |
| | Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 |
| | Variability in the Degree of Expression of Phosphorylated I B in Chronic Lymphocytic Leukemia Cases With Nodal Involvement | Q58010985 |
| | Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing | Q58324020 |
| | Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1) | Q73283069 |
| | PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia | Q89401183 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| | lymphocyte | Q715347 |
| | ibrutinib | Q5984881 |
| | leukemia | Q29496 |
| P304 | page(s) | 3734-3743 | |
| P577 | publication date | 2016-12-29 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells | |
| P478 | volume | 23 | |